<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952898</url>
  </required_header>
  <id_info>
    <org_study_id>GDC-695-001</org_study_id>
    <nct_id>NCT02952898</nct_id>
  </id_info>
  <brief_title>Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gage Development Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gage Development Company, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being done to compare the safety and effectiveness of GDC 695 (test
      drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to
      establish that these two drugs work better than placebo in the treatment of actinic
      keratosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Actual">September 6, 2017</completion_date>
  <primary_completion_date type="Actual">July 11, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Complete Clearance of AK Lesions</measure>
    <time_frame>Day 90 (30 days after completion of 60 days of treatment)</time_frame>
    <description>Complete Clearance was defined as 100% clearance of all Actinic Keratosis (AK) lesions (having a count of zero AKs) in the treatment area (face or bald scalp) at the Day 90 visit (30 Days Post Treatment).</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Day 0 through Day 90</time_frame>
    <description>AEs will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">665</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC 695 gel applied topically as directed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diclofenac sodium gel, 3% applied topically as directed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle gel applied topically as directed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC 695</intervention_name>
    <description>GDC 695 is a topical gel.</description>
    <arm_group_label>Test Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium Gel, 3%</intervention_name>
    <description>Diclofenac sodium gel, 3% is an FDA-approved drug.</description>
    <arm_group_label>Reference Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle gel</intervention_name>
    <description>Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has provided written informed consent.

          -  Immunocompetent male and/or non-pregnant female, 18 years of age or older.

          -  Willing and able to apply the test article(s) as directed, comply with study
             instructions, and commit to all follow-up visits for the duration of the study.

          -  Clinical diagnosis of actinic keratosis.

          -  In good general health and free of any disease state or physical condition.

          -  Women, must be post-menopausal, surgically sterile, or use an effective method of
             birth control with a negative urine pregnancy test (UPT) at the Baseline Visit (Day
             1).

        Exclusion Criteria:

          -  Women who are pregnant, breastfeeding, or are planning to become pregnant or
             breastfeed during the study.

          -  Is currently enrolled in another investigational drug or device study or has used an
             investigational drug or investigational device within 30 days prior to the Baseline
             Visit (Day 1).

          -  Has the need or plans to be exposed to artificial tanning devices or excessive
             sunlight during the study.

          -  Is immunosuppressed (e.g., human immunodeficiency virus [ HIV], systemic malignancy,
             graft host disease, etc.) or is taking medications that suppress the immune system.

          -  Has experienced an unsuccessful outcome from previous topical diclofenac sodium
             therapy.

          -  Has a history of sensitivity to any of the ingredients in the test articles or other
             excipients in the test or reference drug.

          -  Has signs or symptoms consistent with the aspirin (ASA) triad.

          -  Has used topical medications: corticosteroids, alpha hydroxy acids (e.g., glycolic
             acid, lactic acid, etc. &gt;5%), beta hydroxy acid (salicylic acid &gt;2%), urea &gt;2%,
             5-fluorouracil, diclofenac, imiquimod, ingenol mebutate, aminolevulinic acid (ALA) or
             prescription retinoids (e.g., tazarotene, adapalene, tretinoin), over-the-counter
             (OTC) products labeled as scrubs of any kind which are used to smooth the skin (as
             they contain some form of exfoliant such as nut shells, coffee grounds, polymer
             particles, etc.) within the selected treatment area (face or bald scalp) within one
             month prior to the Baseline Visit.

          -  Has had cryodestruction or chemodestruction, curettage, photodynamic therapy (PDT),
             surgical excision, or other treatments for AK within the selected treatment area (face
             or bald scalp) within one month prior to the Baseline Visit.

          -  Has used oral corticosteroid therapy, interferon, cytotoxic drugs, immunomodulators,
             immunosuppressive therapies, or retinoids within one month prior to the Baseline
             Visit.

          -  Has used oral isotretinoin within six months prior to the Baseline Visit.

          -  Has used chemical peels, including but not limited to alphahydroxy acid, betahydroxy
             acid, bichloroacetic acid, trichloroacetic acid, and phenol within the selected
             treatment area (face or bald scalp) within six months prior to the Baseline Visit.

          -  Has had dermatologic procedures or surgeries such as: laser resurfacing, PUVA
             (Psoralen + ultraviolet A) therapy, ultraviolet B (UVB) therapy, ALA-PDT, or
             dermabrasion within the selected treatment area (face or bald scalp) within six months
             prior to the Baseline Visit.

          -  Has lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or
             untreated skin cancers within the selected treatment area (face or bald scalp).

          -  Has active gastrointestinal ulceration or bleeding or has a history of
             gastrointestinal bleeds due to use of aspirin or other NSAIDs.

          -  Has severe renal or hepatic impairment.

          -  Has any condition which, in the investigator's opinion, could interfere with the
             evaluation of the test drugs or that could make it unsafe or preclude the subject's
             ability to fully participate in this research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <results_first_submitted>August 24, 2018</results_first_submitted>
  <results_first_submitted_qc>January 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 10, 2019</results_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solar keratoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02952898/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02952898/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 2016 to July 2017
The location of clinical sites included dermatology clinics and clinical research centers.</recruitment_details>
      <pre_assignment_details>All subjects who met the entry criteria and were randomized and enrolled into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GDC 695 Gel</title>
          <description>The test drug is GDC 695 gel applied topically as directed.
GDC 695: GDC 695 is a topical gel.</description>
        </group>
        <group group_id="P2">
          <title>Diclofenac Sodium Gel</title>
          <description>The reference drug is Diclofenac sodium gel, 3% applied topically as directed.
Diclofenac Sodium Gel, 3%: Diclofenac sodium gel, 3% is an FDA-approved drug.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Vehicle gel applied topically as directed.
Vehicle gel: Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="202"/>
                <participants group_id="P3" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline demographic information is based on the safety population, which includes all randomized subjects who received at least one dose of the test article. Four subjects (2 in Test Drug group, 1 in Reference Drug group, and 1 in Placebo group) were excluded for not applying any test article.</population>
      <group_list>
        <group group_id="B1">
          <title>GDC 695 Gel</title>
          <description>GDC 695 gel applied topically as directed.
GDC 695: GDC 695 is a topical gel.</description>
        </group>
        <group group_id="B2">
          <title>Diclofenac Sodium Gel</title>
          <description>Diclofenac sodium gel, 3% applied topically as directed.
Diclofenac Sodium Gel, 3%: Diclofenac sodium gel, 3% is an FDA-approved drug.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Vehicle gel applied topically as directed.
Vehicle gel: Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="218"/>
            <count group_id="B2" value="220"/>
            <count group_id="B3" value="223"/>
            <count group_id="B4" value="661"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="9.4"/>
                    <measurement group_id="B2" value="69.6" spread="9.8"/>
                    <measurement group_id="B3" value="69.1" spread="9.3"/>
                    <measurement group_id="B4" value="69.6" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="187"/>
                    <measurement group_id="B4" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="207"/>
                    <measurement group_id="B4" value="618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="222"/>
                    <measurement group_id="B4" value="657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="223"/>
                    <measurement group_id="B4" value="661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Complete Clearance of AK Lesions</title>
        <description>Complete Clearance was defined as 100% clearance of all Actinic Keratosis (AK) lesions (having a count of zero AKs) in the treatment area (face or bald scalp) at the Day 90 visit (30 Days Post Treatment).</description>
        <time_frame>Day 90 (30 days after completion of 60 days of treatment)</time_frame>
        <population>Analysis shown is based on the modified Intent-to-Treat (mITT) population, defined as all randomized subjects who met the following requirements, 1) met all inclusion/exclusion criteria; 2) applied at least one dose of test article; 3) and returned for at least one post-baseline evaluation clinic visit (Visits 3, 5, or 6).</population>
        <group_list>
          <group group_id="O1">
            <title>GDC 695 Gel</title>
            <description>GDC 695 gel applied topically as directed.
GDC 695: GDC 695 is a topical gel.</description>
          </group>
          <group group_id="O2">
            <title>Diclofenac Sodium Gel</title>
            <description>Diclofenac sodium gel, 3% applied topically as directed.
Diclofenac Sodium Gel, 3%: Diclofenac sodium gel, 3% is an FDA-approved drug.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Vehicle gel applied topically as directed.
Vehicle gel: Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Complete Clearance of AK Lesions</title>
          <description>Complete Clearance was defined as 100% clearance of all Actinic Keratosis (AK) lesions (having a count of zero AKs) in the treatment area (face or bald scalp) at the Day 90 visit (30 Days Post Treatment).</description>
          <population>Analysis shown is based on the modified Intent-to-Treat (mITT) population, defined as all randomized subjects who met the following requirements, 1) met all inclusion/exclusion criteria; 2) applied at least one dose of test article; 3) and returned for at least one post-baseline evaluation clinic visit (Visits 3, 5, or 6).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="221"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Two-sided, continuity-corrected Chi-square tests was used to evaluate the superiority of GDC 695 gel's complete clearance proportion over that of the Vehicle treatment in the mITT population using LOCF.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Two-sided, continuity-corrected Chi-square tests was used to evaluate the superiority of Diclofenac sodium gel's complete clearance proportion over that of the Vehicle treatment in the mITT population using LOCF.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Events (AEs)</title>
        <description>AEs will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported.</description>
        <time_frame>Day 0 through Day 90</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment Emergent Adverse Events (TEAEs) were collected from study Day 1 (enrollment/first dose) to study completion (Day 90) or participant termination. AEs that continued beyond completion/termination were followed until resolution or stabilization.</time_frame>
      <desc>There were a total of four (4) Serious Adverse Events (SAEs) in three (3) subjects in the Reference group (Diclofenac sodium gel); one of these subjects experienced two (2) SAEs: (1) Bladder transitional cell carcinoma and (2) Haematuria. There were a total of six (6) SAEs in the five (5) subjects in the Placebo group (Vehicle gel); one of these subjects experienced two (2) SAEs: (1) Flank pain and (2) Lung infiltration.</desc>
      <group_list>
        <group group_id="E1">
          <title>GDC 695</title>
          <description>GDC 695 gel applied topically as directed.
GDC 695: GDC 695 is a topical gel.</description>
        </group>
        <group group_id="E2">
          <title>Diclofenac Sodium Gel</title>
          <description>Diclofenac sodium gel, 3% applied topically as directed.
Diclofenac Sodium Gel, 3%: Diclofenac sodium gel, 3% is an FDA-approved drug.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Vehicle gel applied topically as directed.
Vehicle gel: Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="220"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="218"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Application site oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="223"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="218"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="220"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Institution and Investigator, including all employees and coworkers involved with this study, agree not to publish the results of this study without the prior written consent of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gage Development Company</name_or_title>
      <organization>Gage Development Company</organization>
      <phone>1-847-999-0600</phone>
      <email>clinicalinfo@capstonedevservices.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

